multiple myeloma

Bristol Myers culls cell therapy deals with 2 biotechs

BMS has terminated cell therapy pacts with two biotechs amid "portfolio prioritization efforts” within the pharma, one of the affected companies said.

Gabrielle Masson Dec 16, 2024 11:19am

ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma

Nov 5, 2024 3:08pm

An imaginary winners podium is modelled and rendered

Trispecific antibody one-ups Tecvayli in myeloma mouse study

Sep 17, 2024 3:38pm

Graphic image of a red thumbs down against a blue background

FDA rejects Regeneron bispecific, delaying rival to J&J, Pfizer

Aug 21, 2024 5:48am

pivot change turnaround direction walk away

BMS axes bispecific months after filing to run phase 3 trial

Jul 26, 2024 8:17am

multiple myeloma cells blood flow cancer blood cancer

AACR: Regeneron's multiple myeloma drug shows staying power

Apr 7, 2024 4:00pm